NI201800113A - Anticuerpos anti-basigin humanizados y uso de los mismos. - Google Patents

Anticuerpos anti-basigin humanizados y uso de los mismos.

Info

Publication number
NI201800113A
NI201800113A NI201800113A NI201800113A NI201800113A NI 201800113 A NI201800113 A NI 201800113A NI 201800113 A NI201800113 A NI 201800113A NI 201800113 A NI201800113 A NI 201800113A NI 201800113 A NI201800113 A NI 201800113A
Authority
NI
Nicaragua
Prior art keywords
humanized anti
antigen
acid sequence
basigin
binding fragment
Prior art date
Application number
NI201800113A
Other languages
English (en)
Inventor
Chen Zhinan
Zhu Ping
Huang Wan
Zhang Zheng
Zhang Yang
Zhang Mengyao
Bian Huijie
Jiang Jianli
Original Assignee
Fourth Military Medical Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fourth Military Medical Univ filed Critical Fourth Military Medical Univ
Publication of NI201800113A publication Critical patent/NI201800113A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente divulgación proporciona un anticuerpo anti-BASIGIN humanizado o fragmento de unión a antígeno del mismo, que comprende una región variable de cadena pesada (VH) que comprende una secuencia de aminoácidos de la SEQ ID NO: 1; opcionalmente comprende adicionalmente una región variable de cadena ligera (VL) que comprende una secuencia de aminoácidos de la SEQ ID NO: 2. La presente divulagción también proporciona una composición que comprende el anticuerpo anti-BASIGIN humanizado o fragmento de unión a antígeno del mismo, una secuencia de ácidos nucleicos aislada que codifica el anticuerpo anti-BASIGIN humanizado o fragmento de unión a antígeno del mismo, un vector que comprende el ácido nucleico, una célula nafitriona que comprende el vector, y uso del anticuerpo anti-BASIGIN humanizado o fragmento de unión a antígeno del mismo.
NI201800113A 2016-04-29 2018-10-29 Anticuerpos anti-basigin humanizados y uso de los mismos. NI201800113A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610285139.4A CN105820250B (zh) 2016-04-29 2016-04-29 一种抗basigin人源化抗体及其应用

Publications (1)

Publication Number Publication Date
NI201800113A true NI201800113A (es) 2020-01-06

Family

ID=56528099

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201800113A NI201800113A (es) 2016-04-29 2018-10-29 Anticuerpos anti-basigin humanizados y uso de los mismos.

Country Status (26)

Country Link
US (1) US20190270809A1 (es)
EP (1) EP3448892A4 (es)
JP (2) JP7099709B2 (es)
KR (1) KR102369118B1 (es)
CN (2) CN105820250B (es)
AU (1) AU2017255888B2 (es)
BR (1) BR112018072140A2 (es)
CA (1) CA3022308A1 (es)
CL (1) CL2018003072A1 (es)
CO (1) CO2018011663A2 (es)
CR (1) CR20180515A (es)
CU (1) CU24556B1 (es)
DO (1) DOP2018000234A (es)
EC (1) ECSP18084153A (es)
IL (1) IL262588A (es)
MA (1) MA44777A (es)
MX (1) MX2018013176A (es)
MY (1) MY196874A (es)
NI (1) NI201800113A (es)
PE (1) PE20190415A1 (es)
PH (1) PH12018502293A1 (es)
RU (1) RU2755150C2 (es)
SG (1) SG11201809473QA (es)
TN (1) TN2018000358A1 (es)
WO (1) WO2017186182A1 (es)
ZA (1) ZA201807132B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105820250B (zh) * 2016-04-29 2019-04-30 中国人民解放军第四军医大学 一种抗basigin人源化抗体及其应用
BR112020016005A2 (pt) 2018-02-07 2020-12-15 Regeneron Pharmaceuticals, Inc. Método de administração de uma proteína terapêutica ao sistema nervoso central, proteína terapêutica multidomínio, polinucleotídeo, vetor de terapia gênica, e, uso de um nucleotídeo que codifica a proteína terapêutica multidomínio
CN111690062A (zh) * 2019-03-14 2020-09-22 复旦大学 针对恶性疟PfRh5靶点的全人源单克隆抗体及应用
CN110964119A (zh) * 2019-12-05 2020-04-07 沣潮医药科技（上海）有限公司 抗疟二聚体免疫粘附素、药物组合物和用途
CN111420048B (zh) * 2020-03-11 2023-09-19 中国人民解放军第四军医大学 抗basigin人源化抗体用于制备治疗新型冠状病毒肺炎药物的应用
CN113549152B (zh) * 2021-07-22 2023-06-20 中国人民解放军空军军医大学 一种抗basigin人源化抗体及其应用
CN113925963B (zh) * 2021-10-15 2023-08-11 江苏太平洋美诺克生物药业股份有限公司 一种稳定的包含抗cd147单克隆抗体的药物制剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100586960C (zh) * 2006-06-23 2010-02-03 陈志南 HAb18GC2单抗和其轻、重链可变区基因及应用
KR101581279B1 (ko) * 2006-10-27 2015-12-31 엘파스, 인크. 스핑고신-1-포스페이트 결합을 위한 조성물 및 방법
EP2162469A4 (en) * 2007-05-21 2012-08-01 Alderbio Holdings Llc NEW METHODS OF HUMANIZING RABBIT ANTIBODIES AND HUMANIZED RABBIT ANTIBODIES
BRPI0817637A2 (pt) * 2007-09-28 2015-09-08 Chugai Pharmaceutical Co Ltd anticorpo anti-glipican-3 tendo cinéticas aperfeiçoadas no plasma
CN101550416B (zh) * 2008-03-18 2012-01-25 陈志南 人源化单抗Hu-ScFv18的轻、重链可变区基因和其编码多肽及其应用
US8007808B2 (en) * 2008-04-04 2011-08-30 The Board Of Trustees Of The Univeristy Of Illinois Composition and method for facilitating the internalization of a therapeutic agent into a cell
EP2303325A4 (en) * 2008-05-23 2012-09-19 Uti Limited Partnership INHIBITION OF EMMPRIN TO TREAT MULTIPLE SCLEROSIS
EP2379588A2 (en) * 2008-12-30 2011-10-26 Cellartis AB The use of basigin-1 in stem cell and cancer applications
EP2997974B1 (en) * 2009-06-19 2018-06-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of neurodegenerative disorders
PL2496698T3 (pl) * 2009-11-03 2019-07-31 City Of Hope Skrócony receptor naskórkowego czynnika wzrostu (EGFRt) do selekcji transdukowanych komórek T
ES2722300T3 (es) * 2009-12-10 2019-08-09 Hoffmann La Roche Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
WO2011112566A2 (en) * 2010-03-11 2011-09-15 Abbott Laboratories Basigin binding proteins
CN104086654B (zh) * 2014-07-04 2016-06-08 中国人民解放军第四军医大学 人源化修饰型抗CD147嵌合抗体HcHAb18及其应用
CN105820250B (zh) * 2016-04-29 2019-04-30 中国人民解放军第四军医大学 一种抗basigin人源化抗体及其应用

Also Published As

Publication number Publication date
DOP2018000234A (es) 2018-10-31
RU2018138053A (ru) 2020-05-29
CN109476760A (zh) 2019-03-15
EP3448892A4 (en) 2019-10-16
CN105820250B (zh) 2019-04-30
ZA201807132B (en) 2021-05-26
IL262588A (en) 2018-12-31
CN109476760B (zh) 2021-11-12
SG11201809473QA (en) 2018-11-29
US20190270809A1 (en) 2019-09-05
JP2019521648A (ja) 2019-08-08
KR20190020660A (ko) 2019-03-04
WO2017186182A1 (en) 2017-11-02
PH12018502293A1 (en) 2019-07-08
CN105820250A (zh) 2016-08-03
CO2018011663A2 (es) 2019-02-08
KR102369118B1 (ko) 2022-03-03
CU20180129A7 (es) 2019-06-04
ECSP18084153A (es) 2019-03-29
PE20190415A1 (es) 2019-03-19
RU2018138053A3 (es) 2020-08-21
BR112018072140A2 (pt) 2019-02-12
TN2018000358A1 (en) 2020-06-15
MX2018013176A (es) 2019-06-24
EP3448892A1 (en) 2019-03-06
AU2017255888A1 (en) 2018-11-22
JP7099709B2 (ja) 2022-07-12
CU24556B1 (es) 2021-12-08
AU2017255888B2 (en) 2021-01-07
MA44777A (fr) 2019-03-06
CA3022308A1 (en) 2017-11-02
CR20180515A (es) 2019-05-15
CL2018003072A1 (es) 2019-05-31
JP2022084832A (ja) 2022-06-07
MY196874A (en) 2023-05-08
RU2755150C2 (ru) 2021-09-13

Similar Documents

Publication Publication Date Title
NI201800113A (es) Anticuerpos anti-basigin humanizados y uso de los mismos.
UY37694A (es) Dominios de unión a antígeno humanizados y métodos de uso
ECSP20024555A (es) Anticuerpos especificos para cd47 y pd-l1
UY36536A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
ES2621874T3 (es) Anticuerpos para MUC16 y métodos de uso de los mismos
NZ711451A (en) Anti-c5 antibodies having improved pharmacokinetics
MX2021003549A (es) Anticuerpos dobles especificos.
PE20180480A1 (es) Anticuerpos de factor xi y metodos de uso
CR20170026A (es) Anticuerpos anti-tau humanizados
AR101400A1 (es) Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido
AR101846A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
NZ630610A (en) Tau peptides, anti-tau antibodies, and methods of use thereof
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
CO2019001367A2 (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123
CO2018002265A2 (es) Anticuerpos anti-cd19 humano humanizados
AR105267A1 (es) Anticuerpos de unión a tau
PE20230381A1 (es) Proteina de union a rgma
CL2021002792A1 (es) Anticuerpo monoclonal que se une específicamente a gitr
CO2017004753A2 (es) Anticuerpos que se unen a ccr6
AR099604A1 (es) Anticuerpos de metaloproteinasa de matriz 9 y sus métodos de uso
CL2021001104A1 (es) Anticuerpo monoclonal que se une específicamente al antígeno cd20
BR112018006820A2 (pt) anticorpos anti-psa (5a10) humanizados
AR107083A1 (es) Anticuerpos dirigidos a cd32b y métodos de uso de los mismos
AR108451A1 (es) Anticuerpos anti-tenascina modificados y métodos de utilización
AR126364A2 (es) Anticuerpos anti-cd3 y métodos de uso